The medical net on August 21, according to the economic news, world finance, the shortage of drugs is a drug that cannot be properly supplied in a certain area. A reporter's survey found that the price of a shortage of medicines could be tens of times higher in a short period of time. But fighting these actions alone will not relieve the shortage and curb drug prices. How to treat price monopoly?
The cure for the shortage of radical drugs cannot be relied on antitrust alone
On August 14, the national development and reform commission (NDRC) began soliciting opinions on the guidelines for the price behavior of drug and API operators. The solicitation notes suggest that operators may not agree on a horizontal and vertical price monopoly agreement, and that 10 ACTS, such as hoarding and hoarding, will be regarded as price violations. The shortage of drug producers and operators can be disciplined enough to avoid a price monopoly. However, the vice President of China university of political science and law said that the anti-monopoly cannot cure the price chaos of drug shortages.
"Because the anti-monopoly law is not specifically targeted at drugs, it is designed for the whole market," he said. So it USES one of the most abstract (concepts) or the biggest common divisor, and it has its own characteristics when it comes to the drug market."
Underlying causes of drug shortages
In fact, the shortage of drug price monopoly is often a "fire-fighting" behavior. There is a deeper reason for the shortages and the rise of prices, and it highlights the contradictions in the process. In the interview, a number of pharmaceutical companies reflect that production shortages are under management pressure.
The head of a pharmaceutical company said: "because in 2009 when the tender was a one-year investment, the results were not changed after 2009, and kept me performing the 2009 bid. Some products that have been upstream for so many years have raised my price, because environmental pressure is too big, some manufacturers have stopped. I can't execute it. I'm blacklisted if I don't."
Drug bidding needs to be reformed
Examples of this are many, such as resistance to infection of amikacin, now around the wholesale price is in commonly 8 cents a left and right sides, the price and some enterprises in 2009 won the bid price. Over the past eight years, however, the price of the drug has nearly tripled, and businesses have been able to avoid blacklisting. Xu xinyu, director of the anti-monopoly bureau of the national development and reform commission, said new exploration should be made to drug tenders. "Bidding can not blindly to hold down prices, for the shortage of medicine and raw materials, your price pressure too low is basically unprofitable, basic it no one will go to production, don't have this kind of power."
The administration of the shortage of drugs is more than a matter of control
The "tide" phenomenon of shortage drugs is obvious. Sometimes it can't sell, and sometimes it's all over the place. In the production side, however, the supply of shortages was not so elastic due to access restrictions.
"Our survey found that there are a number of enterprises in the approval of many varieties, even only one enterprise. I think it's important to streamline the process of approval, and give them a competitive environment for the manufacturers of the supply of medicines that are in short supply. "Xu said.
Experts pointed out that the control of the shortage of medicines needs the coordination of information monitoring, supply guarantee and circulation management. For drugs are still scarce, fudan university school of public health professor Hu Shan said, can also through the designated production and expand imports to meet supply: "a lot of shortage of medicine it is not a commodity, is small. In this case, as long as the individual patient needs, it is necessary to find a way to produce the product and use this method to solve the problem of shortage." |
